FDA Approves Next-Generation ZOLL® TherOx System for Widowmaker Heart Attack Patients
CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL® Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, announced today it has received U.S. Food and Drug Administration (FDA) approval of the second-generation TherOx System, which provides SuperSaturated Oxygen (SSO2) Therapy and reduces heart muscle damage in “widowmaker” heart attack patients.1 “The TherOx SSO2 Therapy system is another example of ZOLL’s commitment to technology that provi